BlackRock, Inc. 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-25 1:48 pm Purchase |
2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
BlackRock Inc. BLK |
7,453,371 8.500% |
380,690 (+5.38%) |
Filing |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
BlackRock Inc. BLK |
7,072,681 8.600% |
1,738,582 (+32.59%) |
Filing |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
BlackRock Inc. BLK |
5,334,099 7.400% |
321,747 (+6.42%) |
Filing |
| 2021-02-05 07:51 am Purchase |
2020-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
BlackRock Inc. BLK |
5,012,352 7.500% |
1,323,695 (+35.89%) |
Filing |